Bae Jooeun, Munshi Nikhil C, Anderson Kenneth C
Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02215, USA.
Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02215, USA.
Hematol Oncol Clin North Am. 2014 Oct;28(5):927-43. doi: 10.1016/j.hoc.2014.07.002.
Multiple myeloma (MM) is a B-cell malignancy characterized by the clonal proliferation of malignant plasma cells in the bone marrow and the development of osteolytic bone lesions. MM has emerged as a paradigm within the cancers for the success of drug discovery and translational medicine. This article discusses immunotherapy as an encouraging option for the goal of inducing effective and long-lasting therapeutic outcome. Divided into two distinct approaches, passive or active, immunotherapy, which targets tumor-associated antigens has shown promising results in multiple preclinical and clinical studies.
多发性骨髓瘤(MM)是一种B细胞恶性肿瘤,其特征是骨髓中恶性浆细胞的克隆性增殖以及溶骨性骨病变的发展。MM已成为癌症中药物发现和转化医学取得成功的典范。本文讨论免疫疗法,它是实现有效且持久治疗效果目标的一个令人鼓舞的选择。免疫疗法分为被动或主动两种不同方法,靶向肿瘤相关抗原的免疫疗法在多项临床前和临床研究中已显示出有前景的结果。